Funding for this research was provided by:
the National Natural Science Foundation of China (81702248)
Received: 19 February 2022
Accepted: 16 May 2022
First Online: 28 May 2022
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board/Privacy Board at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) (Ethics approval No.: IRB-2021–361). We have to provide complete informed consent for every patient before he or she will undergo gene-test diagnosis and cancer treatment in our hospital. There was an appropriate waiver of IRB for this retrospective analysis. The IRB exempted us from the informed consent for patients’ participation in this study because this study was retrospective design for their clinical data.
: Not Applicable.
: Junrong Yan are the employee of Nanjing Geneseeq Technology Inc.